Status:
RECRUITING
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Conditions:
Incurable Disease
Eligibility:
All Genders
Brief Summary
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Eligibility Criteria
Inclusion
- Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
- Participant must have a life expectancy greater than 3 months
- Participant must have an ECOG performance status 0-2
- Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
- Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.
Exclusion
- None
Key Trial Info
Start Date :
May 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04343365
Start Date
May 5 2020
End Date
March 1 2028
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moffitt Cancer Center
Tampa, Florida, United States, 33613